Geisinger

POLICIES AND PROCEDURE MANUAL

Policy: MBP 322.0

Section: Medical Benefit Pharmaceutical Policy

Subject: Imdelltra (tarlatamab-dlle)

I. Policy:
Imdelltra (tarlatamab-dlle)

II. Purpose/Objective:
To provide a policy of coverage regarding Imdelltra (tarlatamab-dlle)

III. Responsibility:
A. Medical Directors
B. Medical Management
C. Pharmacy Department

IV. Required Definitions
1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than
3. the department requiring/authoring the policy.
4. Devised – the date the policy was implemented.
5. Revised – the date of every revision to the policy, including typographical and grammatical changes.
6. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions
Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;
c. in accordance with current standards good medical treatment practiced by the general medical community;
d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient

Medicaid Business Segment
Medically Necessary — A service, item, procedure, or level of care compensable under the Medical Assistance program that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

i. Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
ii. Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
iii. Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

DESCRIPTION:
Imdelltra (tarlatamab-dlle) is a bispecific T-cell engager (BiTE) therapy that directs T cells to cancer cells expressing delta-like ligand 3 (DLL3), independent of major histocompatibility complex (MHC) class I. DLL3 is a protein that inhibits Notch signaling and is usually localized intracellularly in normal cells but is abnormally expressed on the surface of small cell lung cancer cells, rendering it an ideal target in small cell lung cancer

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

GRANDFATHER PROVISION – Members already established on therapy are eligible for approval as long as there is medical record documentation that the safety and effectiveness of use for the prescribed indication is supported by Food and Drug Administration (FDA) approval or adequate medical and scientific evidence in the medical literature.

Imdelltra (tarlatamab-dlle) will be considered medically necessary for all lines of business when ALL of the following criteria are met:

- Medical record documentation of age greater than or equal to 18 years **AND**
- Medical record documentation that Imdelltra is prescribed by a hematologist or oncologist **AND**
- Medical record documentation of extensive-stage small cell lung cancer (ES-SCLC) (ES-SCLC is classified as SCLC that is Stage IV (T any, N any, M 1a/b/c), or Stages 1-3 with T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan) **AND**
- Medical record documentation of disease progression on or after treatment with platinum-based chemotherapy.

AUTHORIZATION DURATION: Initial approval will be for **6 months**. Subsequent approvals will be for an **additional 6 months** and will require medical record documentation of continued disease improvement or lack of disease progression. The medication will no longer be covered if the member experiences unacceptable toxicity or worsening of disease.

Note: For Medicaid (GHP Family), any requests for services that do not meet criteria set in the PARP will be evaluated on a case-by-case basis.

LINE OF BUSINESS:
Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

REFERENCES:

1. Imdelltra [Package Insert]. Thousand Oaks, CA: Amgen Inc.: May 2024
2. National Comprehensive Cancer Network. NCCN Guidelines for Treatment of Small Cell Lung Cancer [Accessed July 2024]. Available from https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf

This policy will be revised as necessary and reviewed no less than annually**.**

Devised: 7/16/24

Revised:

Reviewed:

MA UM Committee approval: 8/30/24